Corrigendum

Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2

Brandon C. Sos, Charles Harris, Sarah M. Nordstrom, Jennifer L. Tran, Mercedesz Balázs, Patrick Caplazi, Maria Febbraio, Milana A.B. Applegate, Kay-Uwe Wagner and Ethan J. Weiss

Published August 1, 2011

Original citation: J. Clin. Invest. 2011;121(4):1412–1423. doi:10.1172/JCI42894.

Citation for this corrigendum: J. Clin. Invest. 2011;121(8):3360. doi:10.1172/JCI59854.

The dosage for GW9662 was incorrectly noted in Results, Methods, and the legend for Figure 6. The correct sentences appear below.

Results: We treated a cohort of younger animals for 2 weeks at a dose of 4 mg/kg body weight and found that there was a 31% reduction in the expression of Cd36 (Figure 6F) and a 48% reduction in liver TG content in JAK2L animals treated with GW9662 versus those treated with vehicle (Figure 6G).

Methods: Each day, an aliquot of stock drug was thawed and then resuspended in DMSO/saline at a final concentration of 4 mg/kg body weight in a final volume of 100 μl.

Figure 6 legend: (F) Normalized expression of Cd36 from livers of male control and JAK2L mice after a 2-week treatment with the PPARγ-specific antagonist GW9662 (G) (4 mg/kg) or vehicle (V) (n = 5 for each group).

The authors regret the error.